XGN
Exagen Inc (XGN)
Healthcare • NASDAQ • $2.95+0.34%
- Symbol
- XGN
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Price
- $2.95
- Daily Change
- +0.34%
- Market Cap
- $71.22M
- Trailing P/E
- N/A
- Forward P/E
- -6.56
- 52W High
- $12.23
- 52W Low
- $2.59
- Analyst Target
- $8.67
- Dividend Yield
- N/A
- Beta
- 1.81
Exagen Inc. designs, develops, and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of complex rheumatic, and autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company's lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus platform, a cornerstone of the SLE assessment that begins by quantifying the level of CB-CAPs biomarkers (EC4d and BC4d) in the patient's blood; and AVISE APS th…
Company websiteResearch XGN on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.